Sabby Management’s Ocular Therapeutix OCUL Stock Holding History

Sabby Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,115	Closed	-$5.12M	–	199
2021 Q3	$5.12M	Buy	5,115 +3,447	+207%	+$38.7K	0.69%	16
2021 Q2	$2.37M	Buy	1,668 +702	+73%	+$10.7K	0.33%	44
2021 Q1	$1.58M	Buy	+966	New	+$18.6K	0.31%	63
2016 Q1	–	Sell	-100	Closed	-$94K	–	338
2015 Q4	$94K	Sell	100 -15	-13%	-$162	0.01%	299
2015 Q3	$162K	Buy	+115	New	+$2.31K	0.01%	352

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Sabby Management's OCUL Position: Q4 2021 in Review

Sabby Management sold out of Ocular Therapeutix (OCUL) in Q4 2021, closing a stake of 142,000 shares — an estimated $1.42M sold.

Sabby Management first reported a position in OCUL in Q3 2014 and held it in 9 quarters. The position peaked at $2.1M in Q2 2015. 140 funds tracked by Wall St. Rank hold OCUL as of Q4 2021.

Sabby Management reported no remaining Ocular Therapeutix position as of Q4 2021 after selling out during the quarter.
Sabby Management sold 142,000 Ocular Therapeutix shares in Q4 2021, an estimated $1.42M.
Sabby Management first reported a position in Ocular Therapeutix in Q3 2014 and held it in 9 quarters.
Sabby Management's Ocular Therapeutix position peaked at $2.1M in Q2 2015.
140 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.